Drug Profile
Leuprorelin depot - Camurus
Alternative Names: CAM 2032; Leuprolide Acetate FluidCrystal® Injection Depot; ProzenzeLatest Information Update: 18 Nov 2021
Price :
$50
*
At a glance
- Originator Camurus
- Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
- Mechanism of Action Gonadotropin releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Prostate cancer
Highest Development Phases
- Phase II Prostate cancer
Most Recent Events
- 21 Aug 2019 Leuprorelin is still in phase II trial for Prostate cancer in Finland, Hungary (Camurus pipeline, Auguts 2019)
- 22 Jun 2016 Leuprorelin depot - Camurus is available for licensing as of 21 Jun 2016. http://www.camurus.com/
- 21 Jun 2016 Pharmacokinetics and adverse events data from a phase II clinical trial in Prostate cancer released by Camurus